uploads/2018/07/molecule-2082634_1280.jpg

Wall Street Analysts: Mostly Positive on Opko Health in July

By

Updated

Stock performance

On July 11, Opko Health (OPK) stock closed at $6.01, which represents 126% growth from its 52-week low of $2.66 in March.

On Tuesday, July 3, Opko Health stock closed at $4.76 and reached $6.01 on Thursday, July 11, which represents 24% growth over the last week.

Opko Health stock saw consistent growth over the last week with 7.87% and 5.95% growth on July 6 and July 9, respectively.

The stock hit its 52-week high on September 27, 2017.

Article continues below advertisement

 

About Opko Health

Opko Health is focused on the development of pharmaceuticals and diagnostics. It’s one of the leading genetic testing clinical laboratories in the United States.

Its diagnostics business includes bioreference laboratories that facilitate genetic testing. Its notable genetic testing products include the 4Kscore prostate cancer test and the Claros immunoassay platform.

Opko Health’s pharmaceutical products include Rayaldee, which is used for the treatment of individuals with secondary hyperthyroidism and chronic kidney disease, along with vitamin D deficiency.

The company is also conducting a Phase 3 clinical trial for its biologics products hGH-CTP, a growth hormone injection, and its long-acting factor VIIa drug for hemophilia.

Article continues below advertisement

Analyst recommendations

Of the six analysts tracking Opko Health in July, two of them have recommended a “strong buy,” and two have recommended a “buy.” One analyst has recommended a “hold,” and one has recommended a “sell.”

On July 11, Opko Health had a consensus 12-month target price of $11.90, which represents a 98% return on investment over the next 12 months.

Peer ratings

Of the 15 analysts tracking Amneal Pharmaceuticals (AMRX) in July, 47% of the analysts have recommended a “buy,” while the rest of them have recommended a “hold.”

Of the 20 analysts tracking Eli Lilly (LLY) in July, 55% of them have recommended a “buy,” while eight have recommended a “hold,” and one has recommended a “sell.”

Of the 21 analysts tracking Bristol-Myers Squibb (BMY) in July, 33% of them have recommended a “buy,” and 12 have recommended a “hold.” Two analysts have recommended a “sell.”

On July 11, Amneal Pharmaceuticals, Eli Lilly, and Bristol-Myers Squibb had consensus 12-month target prices of $21.50, $91.83, and $57.37, respectively, which represent 18.92%, 4.88%, and 2.91% returns on investment, respectively, over the next 12 months.

Advertisement

More From Market Realist